[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on tumor radiotherapy‐induced coronary artery diseases
Li Hongfei1,2, Zhong Qiuzi3, Zhang Wenduo4
1Department of Cardiology, National Center of Gerontology, Beijing Hospital, Beijing 100730,China; 2Graduate School of Peking Union Medical College, Beijing 100005,China; 3Department of Radiation Oncology, National Center of Gerontology, Beijing Hospital, Beijing 100730,China; 4Department of Cardiology, National Center of Gerontology, Beijing Hospital, Chinese Academy of Medical Sciences, Beijing 100730,China
Abstract In recent years, radiotherapy has been widely applied in tumor patients. The short‐term and long‐term impact on the cardiovascular system has captivated increasing attention from radiologist and cardiologist. Along with higher radiation dose and longer follow‐up, the incidence rate of coronary artery disease tends to significantly elevate, especially in patients with breast cancer and lung cancer. With the advancement of radiotherapy technologies, different tumors, different radiation doses and different modes of radiation delivery exert different effects on coronary artery. There are still some disputes about how to prevent, diagnose, evaluate, and treat the high‐risk population of coronary artery diseases after radiotherapy. How to optimize the treatment strategy before and after radiotherapy to reduce the incidence of short‐term and long‐term coronary artery diseases in cancer patients needs further clinical research.
Li Hongfei,Zhong Qiuzi,Zhang Wenduo. Research progress on tumor radiotherapy‐induced coronary artery diseases[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 754-758.
Li Hongfei,Zhong Qiuzi,Zhang Wenduo. Research progress on tumor radiotherapy‐induced coronary artery diseases[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 754-758.
[1] Darby SC, Ewertz M, McGale P, et al.Risk of ischemic heart disease in women after radiotherapy for breast cancer[J]. N Engl J Med, 2013,368(11): 987‐998.DOI: 10.1056/NEJMoa1209825. [2] Atkins KM, Rawal B, Chaunzwa TL, et al.Cardiac radiation dose, cardiac disease,mortality in patients with lung cancer[J]. J Am Coll Cardiol, 2019,73(23): 2976‐2987.DOI: 10.1016/j.jacc.2019.03.500. [3] Jacobse JN, Duane FK, Boekel NB, et al.Radiation dose‐response for risk of myocardial infarction in breast cancer survivors[J]. Int J Radiat Oncol Biol Phys, 2019,103(3): 595‐604.DOI: 10.1016/j.ijrobp.2018.10.025. [4] van den Bogaard VA, Ta BD, van der Schaaf A, et al.Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three‐dimensional dose distributions to cardiac substructures[J]. J Clin Oncol, 2017,35(11): 1171‐1178.DOI: 10.1200/JCO.2016.69.8480. [5] Ramin C, Schaeffer ML, Zheng Z, et al.All‐cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long‐standing community‐based cohort[J]. J Natl Cancer Inst, 2021,113(2): 137‐145.DOI: 10.1093/jnci/djaa096. [6] Jimenez RB, Wong SM, Johnson A, et al.The association between cardiac mortality and adjuvant radiation therapy among older patients with stage I estrogen positive breast cancer: A Surveillance, Epidemiology, and End Results(SEER)‐based study on cardiac mortality and radiation therapy[J]. Adv Radiat Oncol, 2021,6(2): 100633.DOI: 10.1016/j.adro.2020.100633. [7] Taylor C, Correa C, Duane FK, et al.Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials[J]. J Clin Oncol, 2017,35(15): 1641‐1649.DOI: 10.1200/JCO.2016.72.0722. [8] Morota M, Gomi K, Kozuka T, et al.Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2009,75(1): 122‐128.DOI: 10.1016/j.ijrobp.2008.10.075. [9] Aleman BM, van den Belt‐Dusebout AW, De Bruin ML, et al.Late cardiotoxicity after treatment for Hodgkin lymphoma[J]. Blood, 2007,109(5): 1878‐1886.DOI: 10.1182/blood‐2006‐07‐034405. [10] Van Nimwegen FA, Schaapveld M, Janus CP, et al.Cardiovascular disease after Hodgkin lymphoma treatment: 40‐year disease risk[J]. JAMA Intern Med, 2015,175(6): 1007‐17.doi: 10.1001/jamainternmed.2015.1180. [11] Maraldo MV, Giusti F, Vogelius IR, et al.Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC‐LYSA trials[J]. Lancet Haematol, 2015,2(11): e492‐502.DOI: 10.1016/S2352‐3026(15)00153‐2. [12] Baselet B, Belmans N, Coninx E, et al.Functional gene analysis reveals cell cycle changes and inflammation in endothelial cells irradiated with a single X‐ray dose[J]. Front Pharmacol, 2017,8:213.DOI: 10.3389/fphar.2017.00213. [13] Gaya AM, Ashford RF.Cardiac complications of radiation therapy[J]. Clin Oncol(R Coll Radiol), 2005,17(3): 153‐159.DOI: 10.1016/j.clon.2004.09.016. [14] Ramadan R, Baatout S, Aerts A, et al.The role of connexin proteins and their channels in radiation‐induced atherosclerosis[J]. Cell Mol Life Sci, 2021,78(7): 3087‐3103.DOI: 10.1007/s00018‐020‐03716‐3. [15] Tam SY, Wu VW, Law HK.Influence of autophagy on the efficacy of radiotherapy[J]. Radiat Oncol, 2017,12(1): 57.DOI: 10.1186/s13014‐017‐0795‐y. [16] Sárközy M, Varga Z, Gáspár R, et al.Pathomechanisms and therapeutic opportunities in radiation‐induced heart disease: from bench to bedside[J]. Clin Res Cardiol, 2021,110(4): 507‐531.DOI: 10.1007/s00392‐021‐01809‐y. [17] Belzile‐Dugas E, Eisenberg MJ.Radiation‐induced cardiovascular disease: review of an underrecognized pathology[J]. J Am Heart Assoc, 2021,10(18): e021686.DOI: 10.1161/JAHA.121.021686. [18] Mitchell JD, Cehic DA, Morgia M, et al.Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio‐Oncology Society[J]. JACC CardioOncol, 2021,3(3): 360‐380.DOI: 10.1016/j.jaccao.2021.06.003. [19] Rassaf T, Totzeck M, Backs J, et al.Onco‐cardiology: consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology[J]. Clin Res Cardiol, 2020,109(10): 1197‐1222.DOI: 10.1007/s00392‐020‐01636‐7. [20] Sárközy M, Varga Z, Gáspár R, et al.Pathomechanisms and therapeutic opportunities in radiation‐induced heart disease: from bench to bedside[J]. Clin Res Cardiol, 2021,110(4): 507‐531.DOI: 10.1007/s00392‐021‐01809‐y. [21] Davis M, Witteles RM.Radiation‐induced heart disease: an under‐recognized entity?[J]. Curr Treat Options Cardiovasc Med, 2014,16(6): 317.DOI: 10.1007/s11936‐014‐0317‐2.
2022, Vol. 31 
